Alleged Crime Boss Charged by U.S. for Attempted Trafficking of Weapons-grade Nuclear Material
Takeshi Ebisawa poses with a rocket launcher during a meeting with an informant and two undercover Danish police officers at a warehouse in Copenhagen, Denmark February 3, 2021, in a photograph from a Drug Enforcement Administration (DEA) criminal complaint.
16:05 JST, February 22, 2024
The U.S. Justice Department announced Wednesday that it had indicted Japanese national Takeshi Ebisawa and a Thai national for allegedly attempting to traffic uranium and plutonium, materials that could be used to build nuclear weapons.
Ebisawa, 60, allegedly had been trying since 2020 to make a deal with an undercover Drug Enforcement Administration agent to sell uranium to an Iranian general, according to the DOJ announcement and other documents. He had proposed that an insurgent group in Myanmar sell the uranium through him to fund a weapons purchase.
U.S. authorities analyzed a sample that Ebisawa used for the deal, and confirmed it contained uranium, thorium and plutonium.
Prior to this case, Ebisawa was indicted for attempting to broker a deal between a Myanmar insurgent group and a weapons and illegal drugs dealer in April 2022. The U.S. authority describes Ebisawa as “a leader of the Japanese Yakuza crime syndicate.”
Top Articles in Society
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
15 Measles Patients Confirmed in Tokyo in Past 6 Days; 1 May Have Come into Contact with Many in Shibuya
-
Bus Carrying 40 Passengers Catches Fire on Chuo Expressway; All Evacuate Safely
-
Ibaraki Pref.’s 1st Foreign Bus Driver Hired in Tsukuba
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Japan Figure Skating Legend Yuzuru Hanyu Is Proud Disaster Survivor and Gold Medalist, Vows to Continue Support Efforts
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

